Dupixent (dupilumab) was first approved by the U.S. Food and Drug Administration (FDA) in March 2017 [1]. This initial approval was for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical therapies [1].
When Else Was Dupixent Approved?
Since its initial launch, Dupixent has received expanded approvals for several other conditions. It was approved for moderate-to-severe asthma in adults and adolescents in October 2018 [2]. In November 2019, it gained approval for moderate-to-severe eosinophilic esophagitis in adults and children [3]. Further approvals include chronic rhinosinusitis with nasal polyps in adults in May 2019 [4], and moderate-to-severe atopic dermatitis in adolescents and children aged 6 months and older in June 2020 [5]. Dupixent also received approval for prurigo nodularis in adults in September 2022 [6].
What Are Dupixent's Patent Expirations?
The patent landscape for Dupixent is complex. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Dupixent [7]. As of late 2023, the primary patents for Dupixent are expected to expire in the mid-2030s, with some key patents expiring around 2034-2035 [7]. However, patent challenges and additional patent filings can influence these timelines [7].
Can Generic or Biosimilar Versions Enter the Market Before Patent Expiry?
Generally, generic or biosimilar versions of a drug cannot enter the market until the relevant patents have expired and any periods of market exclusivity have concluded [7]. For biologic drugs like Dupixent, the pathway to market for biosimilars is regulated separately from generics [8]. The specific timing for potential biosimilar entry depends on the expiration of patents covering the drug and its manufacturing processes, as well as any regulatory exclusivity granted by agencies like the FDA [7][8].
What Companies Are Involved with Dupixent?
Dupixent is developed and marketed by Regeneron Pharmaceuticals and Sanofi [1][2][3][4][5][6].
What is Dupixent Used For?
Dupixent is used to treat a range of chronic inflammatory diseases. Its approved indications include:
* Moderate-to-severe atopic dermatitis [1][5]
* Moderate-to-severe asthma [2]
* Moderate-to-severe eosinophilic esophagitis [3]
* Chronic rhinosinusitis with nasal polyps [4]
* Prurigo nodularis [6]
What is the Mechanism of Action for Dupixent?
Dupixent is a monoclonal antibody that inhibits the signaling of two key cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13) [1]. These cytokines are central to the Type 2 inflammation that drives many of the conditions Dupixent treats [1].
What Clinical Data Supports Dupixent's Use?
The efficacy and safety of Dupixent have been demonstrated in numerous clinical trials across its various indications. For instance, pivotal trials for atopic dermatitis showed significant improvements in skin clearing and itch reduction [1]. Asthma studies demonstrated reductions in exacerbations and improvements in lung function [2]. Similarly, trials for eosinophilic esophagitis showed improvements in endoscopic scoring and disease symptoms [3].
What Are the Potential Side Effects of Dupixent?
Common side effects reported with Dupixent include injection site reactions, inflammation of the eye (conjunctivitis), and inflammation of the mouth and throat (oropharyngeal inflammation) [1]. Other potential side effects can vary depending on the specific condition being treated [2][3][4][5][6].
How is Dupixent Administered?
Dupixent is administered via subcutaneous injection [1]. The dosage and frequency of administration depend on the indication and patient age [1].
What are the Treatment Costs for Dupixent?
The cost of Dupixent can vary. Factors influencing the price include insurance coverage, patient assistance programs, and geographical location. Detailed pricing information is typically available through the manufacturer's patient support services or from healthcare providers and pharmacies.
Sources:
[1] https://www.drugpatentwatch.com/product/dupixent
[2] https://www.drugpatentwatch.com/product/dupixent
[3] https://www.drugpatentwatch.com/product/dupixent
[4] https://www.drugpatentwatch.com/product/dupixent
[5] https://www.drugpatentwatch.com/product/dupixent
[6] https://www.drugpatentwatch.com/product/dupixent
[7] https://www.drugpatentwatch.com/product/dupixent
[8] https://www.drugpatentwatch.com/product/dupixent